Dr. Valeria Yartseva is Associate Director for Translational Biology at Kenai Therapeutics. She was recently Principal Scientist of Neuroscience Discovery at BridgeBio Pharma leading multiple early discovery programs to develop antisense oligonucleotide (ASO) and small molecule therapies for neurodegenerative diseases. Previously, she was a scientist in the Neuroscience Department at Genentech where she led research programs across neuromuscular indications including Duchenne Muscular Dystrophy, cell replacement therapy, and ALS.

Dr. Yartseva holds a Bachelor of Arts in neuroscience from University of California, Berkeley, and received her Doctor of Philosophy from Yale University.